Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529410 | 0.79 | CYP11B1 (0.53) | TDP1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL9060998 | 0.75 | TDP1 (0.48) | TDP1SMN1; SMN2LMNATSHRTNF | |
| SCHEMBL8413080 | 0.75 | TDP1 (0.48) | POLBTDP1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL10873867 | 0.74 | KCNMA1 (0.43) | TDP1CYP2C19SMN1; SMN2NPC1RAB9A | |
| SCHEMBL9460847 | 0.73 | POLB (0.40) | POLBTDP1SMN1; SMN2NPC1LMNA | |
| SCHEMBL11451311 | 0.72 | TDP1 (0.46) | POLBTDP1SMN1; SMN2LMNATSHR | |
| SCHEMBL10962344 | 0.72 | POLB (0.49) | POLBMKNK1MKNK2TDP1CYP1A2 | |
| SCHEMBL8792548 | 0.72 | TDP1 (0.46) | TDP1SMN1; SMN2LMNATSHRTNF | |
| SCHEMBL6530090 | 0.72 | TDP1 (0.46) | POLBTDP1SMN1; SMN2NPC1LMNA | |
| SCHEMBL4313381 | 0.72 | CYP11B1 (0.62) | TDP1SMN1; SMN2LMNAALDH1A1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889873-B2 | Process for the preparation of enantiomerically enriched proton pump inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2014-11-18 | — | — | US | disclosed |
| US-20120046319-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-23 | — | — | US | disclosed |
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| EP-2350050-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | LEK Pharmaceuticals d.d. (SI) | 2011-08-03 | — | — | EP | disclosed |
| EP-2264024-A1 | Process for the preparation of enantiomerically enriched proton pump inhibitors | LEK Pharmaceuticals d.d. (SI) | 2010-12-22 | — | — | EP | disclosed |
| WO-2010043601-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2010-04-22 | — | — | WO | disclosed |
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | disclosed |
| CN-1767817-A | Oral pharmaceutical formulation for proton pump antagonists | ALTANA PHARMA AG (DE) | 2006-05-03 | — | — | CN | disclosed |
| US-6998490-B2 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. (IT) | 2006-02-14 | — | — | US | disclosed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | POLB 3346/4885MKNK1 3284/4885MKNK2 3148/4885 |
| US-20040192929-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group | STS, MPST, SULT2A1 | POLB 3802/4885MKNK1 3244/4885MKNK2 3237/4885 |
| US-20120046319-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | PPOX, HPD, HRH2 | POLB 648/4885MKNK1 2931/4885MKNK2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.